CDH-Backed Drug Developer Innorna Is Said to Plan Hong Kong IPO
PositiveTechnology

Innorna Co., a Chinese company specializing in messenger RNA drugs and backed by CDH Investments, is gearing up for an initial public offering in Hong Kong. This move is significant as it highlights the growing interest and investment in innovative biotech solutions, particularly in the mRNA sector, which has gained prominence due to its role in vaccine development. An IPO could provide Innorna with the capital needed to expand its research and development efforts, potentially leading to breakthroughs in drug therapies.
— Curated by the World Pulse Now AI Editorial System